ClinicalTrials.gg
RecruitingNCT04119102Updated Apr 30, 2020

Duobrii in Combination With Biologics

A Phase 4 interventional study of Duobrii in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-30.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2020, 6 years 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.

Planned enrollment
7th of 12
25 · median 27
Started
2019
with 2 others
Phase 4
11 of 13
4 open now
Registered
9th of 13
by date

Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2019, is one of 11 in phase 4, and was the 9th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, or all of them as a file.
02

Study summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Read the detailed description

A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age;
  2. Diagnosis of chronic plaque-type
  3. Psoriasis affecting 2%-10% BSA
  4. Patient is being treated with biologic therapy for a minimum of 24 weeks
  5. Able and willing to give written prior to performance of any study-related procedures

Exclusion criteria

Exclusion Criteria:

  1. Psoriasis affecting ˂2% or >10% BSA
  2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
  3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
  4. Has previously used DUOBRII
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Open Label Duobrii

    Duobrii QD

    Drug: Duobrii

Interventions

  • DrugDuobrii

    duobrii applied daily for 4 weeks followed by every other day for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Body surface area improvement

    body surface area determined by palm method where 1 palm is equivalent to 1%

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
    Recruiting
    • Elise Nelson · Contactenelson@windsordermatology.com · 609-443-4500
    • Jerry Bagel, MD · Principal investigator
    • Brian Keegan, MD, PhD · Sub investigator
    • David Nieves, MD · Sub investigator
    • Alexa Hetzel, PA-C · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Aug 2020, 9 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 9 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2019
First posted
Oct 8, 2019
StartActual
Oct 14, 2019
Primary completionEst.
Aug 1, 2020
CompletionEst.
Sep 1, 2020
Last update
Apr 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04119102
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Collaborators
Ortho Dermatologics
Responsible party
Sponsor
First posted
Oct 8, 2019
Start date
Oct 14, 2019
Primary completion
Aug 1, 2020 (estimated)
Completion
Sep 1, 2020 (estimated)
Last update
Apr 30, 2020

Study contacts

Jerry Bagel, MD
Contact
dreamacres1@aol.com
6094434500
Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion